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Abstract
The urokinase-type plasminogen activator receptor (uPAR), a glycosylphosphatidylinositol (GPI) anchored membrane
protein, regulates urokinase (uPA) protease activity, chemotaxis, cell-cell interactions, and phagocytosis of apoptotic cells.
uPAR expression is increased in cytokine or bacteria activated cell populations, including macrophages and monocytes.
However, it is unclear if uPAR has direct involvement in the response of inflammatory cells, such as neutrophils and
macrophages, to Toll like receptor (TLR) stimulation. In this study, we found that uPAR is required for optimal neutrophil
activation after TLR2, but not TLR4 stimulation. We found that the expression of TNF-a and IL-6 induced by TLR2
engagement in uPAR-/- neutrophils was less than that in uPAR+/+ (WT) neutrophils. Pretreatment of neutrophils with PI-
PLC, which cleaves GPI moieties, significantly decreased TLR2 induced expression of TNF-a in WT neutrophils, but
demonstrated only marginal effects on TNF-a expression in PAM treated uPAR-/- neutrophils. IkB-a degradation and NF-kB
activation were not different in uPAR-/- or WT neutrophils after TLR2 stimulation. However, uPAR is required for optimal p38
MAPK activation after TLR2 engagement. Consistent with the in vitro findings that uPAR modulates TLR2 engagement
induced neutrophil activation, we found that pulmonary and systemic inflammation induced by TLR2, but not TLR4
stimulation is reduced in uPAR-/- mice compared to WT counterparts. Therefore, our data suggest that neutrophil
associated uPAR could be a potential target for treating acute inflammation, sepsis, and organ injury related to severe
bacterial and other microbial infections in which TLR2 engagement plays a major role.
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Introduction
Host immune cells, including macrophages and neutrophils,
recognize and respond to microbial pathogen invasion using
pattern recognition receptors (PRRs), including Toll like receptors
(TLRs), Nod-like receptors (NLRs), and RIG-I-like receptors
(RLRs) [1,2,3,4,5]. TLRs were the first group of PRRs identified
more than a decade ago [5]. Each TLR binds to and is activated
by a unique spectrum of molecules, termed pathogen associated
molecular patterns (PAMPs), that are present in microbial
organisms [1,2,3,4]. TLR2 and TLR4 recognize major molecular
components, such as lipoglycans, lipoteichoic acid (LTA),
peptidoglycan, and lipopolysaccharide (LPS), that are present on
the surface of gram-positive and gram-negative bacteria [1,2,3,4].
More recently, a number of intracellular molecules, such as
HMGB1 and heat shock proteins, that are released to extracellular
milieu by activated cell populations, have been shown to bind and
activate specific TLRs [6,7]. These endogenous molecules have
been termed as damage associated molecular patterns (DAMPs)
[6,7]. Engagement of TLR2 or TLR4 leads to activation of
transcription factors, including NF-kB, and enhances the produc-
tion of pro-inflammatory and immunoregulatory cytokines
[1,2,3,4].
The urokinase-type plasminogen activator receptor (uPAR) was
initially identified through its interaction with urokinase-type
plasminogen activator (uPA), and consists of three globule like
domains (D1, D2, and D3), but lacks trans-membrane and
cytoplasmic structures [8,9,10]. Instead, uPAR is anchored on the
cell membrane through a glycosylphosphatidylinositol (GPI)
moiety [8,9,10]. uPAR can be released from the plasma
membrane by GPI-specific phospholipase C or D to form soluble
uPAR (suPAR) [8]. uPAR itself does not transduce extracellular
signals. However, association between uPAR and other membrane
proteins, such as integrins, enables uPAR to participate in the
activation of downstream signaling events [8,9].
A primary function of uPAR is binding to uPA and thereby
concentrating the protease activity of uPA on the leading edge of
migrating cells [8,9,10]. However, uPAR has a number of
protease-independent activities [8,9,10]. For example, uPAR
regulates cell migration, chemotaxis, cell-cell interaction, and
phagocytosis of apoptotic cells through its interaction with
integrins [8,9,10,11,12,13,14].
uPAR expression is increased in cytokine or bacteria activated cell
populations including macrophages and monocytes, and contributes to
the infiltration of inflammatory cells into infected tissues or organs
[15,16,17,18,19]. However, it is unclear if uPAR has direct
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25843involvement in the response of inflammatory cells, such as neutrophils
and macrophages, to TLR stimulation. Here, we found that uPAR is
required for optimal neutrophil activation through TLR2 engagement.
Results
uPAR is required for neutrophil activation upon TLR2
stimulation
In our previous studies, we found that uPA and plasminogen
activator inhibitor 1 (PAI-1) enhance the inflammatory response of
neutrophils to TLR4 stimulation [20,21,22]. Furthermore, we and
others demonstrated that vitronectin participates in cellular
activation upon both TLR2 and TLR4 stimulation [23,24].
Because uPA, PAI-1, and vitronectin are either ligands for, or
indirectly associated with uPAR [25], we therefore examined the
role of uPAR in the regulation of cellular activation after TLR2 or
TLR4 engagement.
Bone marrow neutrophils isolated from wild type (WT) and
uPAR knockout (uPAR-/-) mice were stimulated with the specific
synthetic TLR2 ligand, PAM3CSK4 (PAM). As shown in
Figure 1A, uPAR-/- neutrophils produced less TNF-a and IL-6
after PAM stimulation than did WT neutrophils. These data
suggest that uPAR participates in neutrophil activation in response
to TLR2 stimulation. Of note, we confirmed that uPAR-/-
neutrophils showed no uPAR expression (Figure 1B).
uPAR cleavage by PI-PLC attenuates neutrophil
activation upon TLR2 stimulation
uPAR is a GPI anchored protein and can be released from the
plasma membrane by the GPI-specific phospholipases C (PI-PLC)
and D [8]. We reasoned that neutrophils isolated from WT mice
after cleavage of uPAR with PI-PLC may resemble uPAR-/-
neutrophils in their response to TLR2 stimulation. To test this
hypothesis, WT neutrophils were pre-treated with PI-PLC and
then stimulated with PAM. As shown in Figure 2A, PI-PLC
pretreatment significantly diminished PAM stimulated TNF-a
expression. However, PI-PLC pretreatment had only minimal
effects on PAM induced TNF-a expression in uPAR-/- neutro-
phils. These data suggest that uPAR, but not other GPI anchored
proteins, has a major role in neutrophil activation upon TLR2
stimulation. Of note, PI-PLC treatment decreased uPAR levels on
WT neutrophils (Figure 2B).
To determine if direct interactions between uPAR and its
ligands are required for the involvement of uPAR in TLR2
induced neutrophil activation, WT neutrophils were pre-treated
with anti-uPAR or control antibodies and then stimulated with
PAM. As shown in Figure 2C, anti-uPAR antibodies had minimal
effects on PAM stimulated TNF-a expression in WT neutrophils.
These data suggest that the ability of uPAR to enhance neutrophil
activation by TLR2 is independent of association of uPAR with its
ligands, but rather requires the structural presence of uPAR that
Figure 1. uPAR is required for neutrophil activation upon TLR2 stimulation. (A) 1610
6 WT and uPAR-/- neutrophils were treated with 1 mg/
ml PAM for 0, 2, or 4 hours, and the levels of TNF-aand IL-6 in the supernatants determined. Neutrophils from 3–4 mice were pooled and equally
divided into indicated treatment groups. n=3 for each condition; Mean 6 SD. The levels of TNF-a and IL-6 in the supernatants of stimulated uPAR-/-
neutrophils were significantly less than those of stimulated WT cells. One representative experiment is shown. Three other independent experiments
provided similar results. (B) 4610
6 WT and uPAR-/- neutrophils were treated with 1 mg/ml PAM for 0, 15, 30, 60 or 120 minutes. The cells were
collected and cellular extracts prepared. The levels of uPAR were determined by Western blotting. The levels of actin were used as loading controls.
doi:10.1371/journal.pone.0025843.g001
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associated ligands.
uPAR is not involved in the transcription of
pro-inflammatory cytokines upon TLR2 stimulation
in neutrophils
We have shown above that the secreted levels of TNF-a by
PAM stimulated uPAR-/- neutrophils are significantly less than
those generated by PAM stimulated WT neutrophils. We next
asked if the diminished expression of TNF-a by uPAR-/-
neutrophils is due to decreased transcriptional activation. To
address this issue, WT and uPAR-/- neutrophils were treated with
PAM for 0, 2, or 4 hours and the levels of mRNA for TNF-a and
IL-1b were determined by realtime PCR. As shown in Figure 3A,
the expression of TNF-a and IL-1b mRNA was similar in PAM
stimulated WT and uPAR-/- neutrophils. We also determined the
mRNA levels of TNF-a, IL-1b, and IL-6 at early time points after
PAM stimulation and did not find significant differences in the
expression of these cytokines by WT and uPAR-/- neutrophils
(Figure 3B). However, it is possible that the significantly lower
levels of TNF-a in the supernatants of PAM treated uPAR-/-
neutrophils is caused by a deficiency in the process of cytokine
secretion. To test this hypothesis, WT and uPAR-/- neutrophils
were lysed after PAM stimulation and the total levels of TNF-a in
the supernatants and cellular extracts were determined. As shown
in Figure 3C, total levels of TNF-a in the supernatants and cellular
extracts from PAM treated uPAR-/- neutrophils were less than
those from PAM treated WT neutrophils. These data suggest that
although the transcription of cytokines was not different in WT
and uPAR-/- cells, there is reduced production of pro-inflamma-
tory cytokines in PAM treated uPAR-/- neutrophils as compared
to that by PAM treated WT neutrophils.
uPAR is not involved in NF-kB activation after TLR2
stimulation in neutrophils
Upon TLR2 stimulation, the TLR2 intracellular domain
recruits the adaptor molecule, MyD88, as well as IRAK1 and
IRAK4, leading to the activation of kinases, including IKK, p38,
Figure 2. uPAR cleavage by PI-PLC attenuates neutrophil activation upon TLR2 stimulation. (A) 2610
6 WT and uPAR-/- neutrophils were
pre-treated without or with 1 U/ml PI-PLC for 1.5 hours. The cells were then collected by centrifugation, washed twice with PBS, and treated with
1 mg/ml PAM for 4 hours. The supernatants were collected and the levels of TNF-a determined. n=3 for each condition; Mean 6 SD; ***p,0.001
when compared to WT neutrophils pretreated without PI-PLC. One representative experiment is shown. A second independent experiment provided
similar results. (B) Experiments were performed as in A. Levels of uPAR and actin were determined by Western blotting. Densitometric analysis was
performed, and the ratios of uPAR/actin calculated. The uPAR/actin ratio in untreated group was considered to be 1. The values in PI-PLC treated cells
are shown as the ratio to that of the untreated group. Representative blots from two independent experiments are shown. (C) 2610
6 WT neutrophils
were pre-treated with 5 mg/ml control IgG or anti-uPAR antibodies for 1 hour. The cells were then collected by centrifugation, washed twice with PBS,
and treated without or with 1 mg/ml PAM for 4 hours. The supernatants were collected and the levels of TNF-a determined.
doi:10.1371/journal.pone.0025843.g002
uPAR Mediates TLR2 Induced Neutrophil Activation
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25843and Erk. IKK kinases phosphorylate IkB-a, causing its
ubiquitination and degradation by the 26S proteasome and
resulting in NF-kB nuclear translocation [1,2,3,4]. To determine
if uPAR participates in the regulation of TLR2 related signaling
events, we examined the levels of IkB-a in PAM treated WT and
uPAR-/- neutrophils. As shown in Figure 4A (IkB-a panel), there
was virtually no difference in IkB-a degradation between PAM
treated WT and uPAR-/- neutrophils. There was also no
difference in DNA binding activity of NF-kB between WT and
uPAR-/- neutrophils (Figure 4B). These data, showing similar
degrees of degradation of IkB-a and of nuclear translocation of
NF-kB in WT and uPAR-/- neutrophils, indicate that uPAR
does not contribute in modulating TLR2 induced NF-kB
activation.
Figure 3. uPAR is not involved in the transcription of pro-inflammatory cytokines upon TLR2 stimulation in neutrophils. (A)
1610
6 WT and uPAR-/- neutrophils were treated with 1 mg/ml PAM for 0, 2, or 4 hours. The cells were collected and total RNA from the cells purified.
The mRNA levels of TNF-a and IL-1b in the cells were determined by real-time PCR. n=3 for each condition; Mean 6 SD; All p values were greater
than 0.05. (B) 1610
6 WT and uPAR-/- neutrophils were treated with 1 mg/ml PAM for 0, 45, or 90 min. The mRNA levels of TNF-a, IL-1b, and IL-6 in the
cells were determined by real-time PCR. n=3 for each condition; Mean 6 SD; All p values were greater than 0.05. (C) 1610
6 WT and uPAR-/-
neutrophils were treated with 1 mg/ml PAM for 4 hours. The supernatants and the neutrophils were collected and cellular extracts prepared. The
supernatants and the cellular extracts were mixed and the levels of TNF-a in the mixture were determined by ELISA assays. n=3 for each condition;
Mean 6 SD. Results from two independent experiments are shown.
doi:10.1371/journal.pone.0025843.g003
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engagement in neutrophils
TLR2 stimulation results in activation of p38 and ERK MAPKs
[1,2,3,4]. Since we did not find evidence of involvement of uPAR
in regulating TLR2 stimulated IkB-a degradation or NF-kB
activation, we next sought to determine if uPAR is involved in
MAPK activation after TLR2 stimulation. As shown in Figure 4A
(p-p38 panel), phosphorylation of p38 is markedly attenuated in
PAM stimulated uPAR-/- as compared to WT neutrophils.
However, TLR2 induced ERK activation was comparable
between WT and uPAR-/- neutrophils (data not shown). These
data suggest that uPAR selectively regulates the TLR2 induced
activation of p38, but not Erk.
TLR2 induced pulmonary inflammatory responses are
attenuated in uPAR-/- mice
In the above experiments, we demonstrated that uPAR
participates in modulating TLR2 induced neutrophil activation
Figure 4. uPAR is not involved in NF-kB activation, but is required for maximal p38 MAPK activation after TLR2 stimulation in
neutrophils. (A) 4610
6 WT and uPAR-/- neutrophils were treated with 1 mg/ml PAM for 0, 7, 15, 30, 60 or 120 minutes. The cells were collected and
cellular extracts prepared. The levels of IkB-a, phosphorylated p38 (p-p38) and GAPDH were determined by Western blotting. The ratios of IkB-a/
GAPDH and p-p38/GAPDH were calculated. The ratio in the WT group at time 0 was regarded as 1. The values for all other conditions were the
relative ratios to the WT group at time 0. Representative blots from two independent experiments are shown. (B) 4610
6 WT and uPAR-/- neutrophils
were treated with 1 mg/ml PAM for 0, 15, 30, 60, 90 or 120 minutes. The cells were collected and nuclear extracts prepared. The DNA binding activity
of p65 was determined by EMSA assay.
doi:10.1371/journal.pone.0025843.g004
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mediating acute inflammatory lung injury [26,27,28,29], we next
sought to determine if uPAR is involved in regulating inflamma-
tory response and tissue injury in the lungs after TLR2
engagement. As shown in Figure 5A, BAL levels of TNF-a were
significantly less in PAM treated uPAR-/- mice than in WT
counterparts. Neutrophil numbers in BAL were also significantly
lower in PAM treated uPAR-/- as compared to WT mice
(Figure 5B). Furthermore, protein concentration in BAL, an index
of lung leak, was markedly less in PAM treated uPAR-/- than in
WT mice (Figure 5C).
TLR2 induced systemic inflammatory responses are
attenuated in uPAR-/- mice
To define the role of uPAR in the regulation of TLR2 induced
inflammatory responses, WT and uPAR-/- mice were given
intraperitoneal PAM and serum levels of TNF-a measured
24 hours later. As shown in Figure 5D, serum levels of TNF-a
were markedly less in uPAR-/- mice given intraperitoneal PAM
than those present in the WT counterparts. These data confirm
that uPAR participates in the modulation of TLR2 induced
inflammatory responses in vivo.
uPAR is not required for neutrophil activation upon TLR4
stimulation
Given the participation of uPAR in TLR2 induced activation of
neutrophils, we next asked if uPAR is also required for neutrophil
activation upon TLR4 engagement. In these experiments, WT
and uPAR-/- neutrophils were cultured with the TLR4 ligand,
LPS, and the secreted levels of TNF-a measured. As shown in
Figure 6A, there was no difference in the production of TNF-a
between LPS treated WT and uPAR-/- neutrophils. These data
suggest the uPAR specifically regulates neutrophil activation by
TLR2, but not TLR4, stimulation.
uPAR does not participate in TLR4 induced pulmonary or
systemic inflammatory responses
Although our in vitro experiments did not demonstrate a role for
uPAR in modulating TLR4 induced neutrophil activation, we
wished to confirm this lack of interaction between TLR4 and
uPAR under in vivo conditions. For this purpose, WT and uPAR-/-
mice were given LPS intratracheally and inflammatory responses
in the lungs determined 24 hours later. As shown in Figures 6B–D,
BAL levels of TNF-a, airway neutrophil numbers, and BAL
protein concentrations were similar in LPS treated WT and
uPAR-/- mice. These data confirm that uPAR is not involved in
TLR4 induced neutrophil activation.
uPAR does not participate in TLR2 or TLR4 induced
macrophage activation
The above experiments demonstrated that uPAR participates in
TLR2, but not TLR4 mediated neutrophil activation. To
determine if uPAR has similar effects on macrophage activation,
peritoneal macrophages from WT and uPAR-/- mice were treated
with PAM or LPS. As shown in Figure 7A, the secreted levels of
TNF-a were comparable between WT and uPAR-/- peritoneal
macrophages after PAM or LPS stimulation. We also performed
similar experiments using alveolar macrophages isolated from WT
and uPAR-/- mice and found there was no difference in the
secreted levels of TNF-a by the alveolar macrophages obtained
from the two groups of mice (Figure 7B). Of note, we confirmed
that uPAR-/- macrophages demonstrated no uPAR expression
(Figure 7C). These data suggest that uPAR does not participate in
TLR2 or TLR4 mediated macrophage activation.
To confirm the lack of participation of uPAR in TLR2 or TLR4
induced macrophage activation, we knocked down uPAR in WT
macrophages using specific siRNA targeting uPAR. As shown in
Figure 7D, uPAR expression was markedly decreased in WT
macrophages transfected with uPAR siRNA as compared to those
transfected with non-targeting control siRNA. Similar to uPAR-/-
macrophages, WT macrophages with uPAR knockdown and
stimulated with either LPS or PAM produced TNF-a at levels
comparable to WT macrophages transfected with control siRNA
(Figure 7E).
To explore mechanisms that might explain the apparently
different contribution of uPAR to TLR2 activation in neutrophils
and macrophages, we examined the relative expression of uPAR
in neutrophils and macrophages. Surprisingly, we found that
uPAR from macrophages demonstrated a smaller molecular
weight than does uPAR from neutrophils (Figure 7F).
Discussion
uPAR is a GPI anchored protein that lacks transmembrane and
intracellular domains. The primary function of uPAR is to serve as
the receptor for uPA, thus concentrating the protease activity of
uPA in the proximity of cell surface. uPAR also has protease-
independent activities in that it participates in the regulation of cell
migration, chemotaxis, cell-cell interaction, and phagocytosis of
apoptotic cells [8,9,10,11,12,13,14]. In the present study, we
describe a novel role for uPAR in modulating TLR2 mediated
neutrophil activation. Consistent with the central role that
Figure 5. TLR2 induced pulmonary and systemic inflammatory
responses are attenuated in uPAR-/- mice. (A–C) WT and uPAR-/-
mice were instilled intratracheally (i.t.) with PAM (200 mg/mouse in 50 ml
PBS). 24 hours after PAM instillation, the mice were sacrificed and BAL
fluids collected. The BAL levels of TNF-a were determined by ELISA (A),
neutrophils in the BAL counted (B), and BAL protein concentrations (C)
determined. (D) WT and uPAR-/- mice were injected intraperitoneally
(i.p.) PAM (200 mg/mouse in 200 ml PBS). 6 hours after PAM injection,
blood was withdrawn retro-orbitally and serum prepared. Serum TNF-a
levels were determined by ELISA. n=4–5, mean 6 SEM, **p,0.01 when
compared to WT group.
doi:10.1371/journal.pone.0025843.g005
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we also found that uPAR-/- mice are protected from TLR2
mediated inflammatory response and lung injury.
In these experiments, we found that the presence of uPAR
results in enhanced production of the pro-inflammatory cytokines
by neutrophils stimulated with PAM, a specific TLR2 ligand. The
differential responses to PAM stimulation of WT and uPAR-/-
neutrophils were significant in each independent experiment,
although statistical analyses were not performed on results
combined from multiple independent experiments due to different
cell number used each time. However, there was no apparent
difference in IkB-a degradation and subsequent NF-kB activation
in PAM treated WT and uPAR-/- neutrophils. Consistent with
such findings, there was no difference in the transcription of
proinflammatory cytokines, such as TNF-a, IL-1b, and IL-6,, as
determined by evaluation of mRNA levels, in PAM treated WT
and uPAR-/- neutrophils. These data suggest that uPAR is not
involved in signaling events downstream of IKK kinase activation
in TLR2 stimulated neutrophils, but rather participates in
modulating posttranscriptional regulation of the expression of
cytokines.
We found no involvement of uPAR in modulating IkB-a
degradation in TLR2 activated neutrophils. However, there was
markedly less activation of p38 in PAM treated uPAR-/-
neutrophils than in PAM treated WT cells. Although TLR
stimulation leads to activation of both IKK kinases and MAPKs,
previous studies showed that such activation can be divergent in
response to some extracellular stimuli [30,31]. Our data suggest
that uPAR may be involved in signaling events leading to
activation of MAPKs, specifically p38, in TLR2 stimulated
neutrophils. Of note, p38 activation has been shown to regulate
post-transcriptional events, such as TNF-a expression, in neutro-
phils and other cell populations [32,33,34,35]. Defective p38
activation in PAM-treated uPAR-/- neutrophils may contribute to
the reduced production of pro-inflammatory cytokines after TLR2
ligation. We also explored potential direct association between
uPAR and TLR2. However, we were unable to find any
interaction between uPAR and TLR2 or CD14 (data not shown).
Therefore, the uPAR associated proteins that differentially
regulate PAM induced p38 MAPK activation and neutrophil
activation remain to be determined.
We found no apparent involvement of uPAR in TLR4 induced
neutrophil activation or in acute lung injury produced by LPS
exposure. The mechanisms responsible for the different involve-
ment of uPAR with TLR2 and TLR4 signaling may relate to the
distinct requirement for co-factors in TLR4 associated cellular
activation [1,2,3,4].
Unlike the potentiating role of uPAR for TLR2 induced
neutrophil activation, there was no evidence that uPAR is involved
in macrophage activation after TLR2 engagement. The differing
participation of uPAR during TLR2 induced activation of
neutrophils and macrophages is surprising as, to our knowledge,
there is no cellular molecule that differentially regulates the
responses of macrophage and neutrophils to TLR stimulation.
However, we found that uPAR on the neutrophil surface
demonstrated slower migration than did macrophage associated
Figure 6. uPAR is not required for neutrophil activation upon TLR4 stimulation. (A) 1610
6 WT and uPAR-/- neutrophils were treated with
10 ng/ml LPS for 4 hours and the levels of TNF-a in the supernatants determined. Mean+SD. (B–D) WT and uPAR-/- mice were given LPS
intratracheally (50 mg/mouse in 50 ml PBS). 24 hours after LPS instillation, the mice were sacrificed and BAL fluids collected. BAL levels of TNF-a were
determined by ELISA (B), neutrophils in BAL counted (C), and BAL protein concentrations determined (D). 4–5 mice in each group, mean 6 SEM. All p
values were greater than 0.05. n.s. indicates non-significant between groups.
doi:10.1371/journal.pone.0025843.g006
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molecular weight for neutrophil uPAR. We sequenced uPAR
cDNA from neutrophils and macrophages and found that the
cDNAs from the two cell populations were identical (data not
shown). These data suggest that uPAR on the neutrophil surface
differs from that on the macrophage because of posttranslational
modifications. These findings are consistent with previous studies
in various cell populations demonstrating the presence of different
forms of uPAR [25]. Our data suggest that a neutrophil specific
modification of uPAR contributes to the regulation of TLR2
mediated activation. Future work will be necessary to further
characterize the nature of such neutrophil associated modifications
in uPAR and also how such a modification regulates the
transduction of TLR2 mediated signaling events.
We found that uPAR-/- mice are protected from TLR2
mediated inflammation and lung injury. Neutrophils play a central
role in mediating inflammation in response to infection and tissue
injury [26,27,28,29]. Because uPAR-/- neutrophils produce
diminished amounts of pro-inflammatory cytokines upon TLR2
stimulation in vitro, it is likely that diminished activation of
Figure 7. uPAR does not participate in TLR2 or TLR4 induced macrophage activation. (A) 0.25610
6 WT and uPAR-/- peritoneal
macrophages were treated with 1 mg/ml PAM or 10 ng/ml LPS for 4 hours and the levels of TNF-a in the supernatants determined. (A) 0.2610
6 WT
and uPAR-/- alveolar macrophages were treated with 1 mg/ml PAM or 10 ng/ml LPS for 4 hours and the levels of TNF-a in the supernatants
determined. (C) 1610
6 WT and uPAR-/- macrophages were treated with 1 mg/ml PAM for 0, 15, 30, 60 or 120 minutes. The cells were collected and
cellular extracts prepared. The levels of uPAR were determined by Western blotting. (D) 1610
6 WT and uPAR-/- macrophages were transfected with
control siRNA or uPAR siRNA. Three days after transfection, the cells were collected and the levels of uPAR and actin determined by Western blotting.
(E) 1610
6 WT and uPAR-/- neutrophils were transfected with control or uPAR siRNA. Three days after transfection, the cells were treated with 1 mg/ml
PAM or 10 ng/ml LPS for 0, 2, or 4 hours and TNF-a levels in the supernatants measured. (F) The levels of uPAR and actin in WT and uPAR-/-
neutrophils and WT macrophages were determined by Western blotting. Results in A, B, C and F were representative of three independent
experiments. Mean 6 SD; All p values were greater than 0.05. n.s. indicates statistically non-significant differences between groups.
doi:10.1371/journal.pone.0025843.g007
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response and lung injury in PAM treated mice. Previous studies
suggested that uPAR plays a detrimental role in hyperoxia-
induced lung injury and that uPAR deficiency is associated with
diminished neutrophil influx into both lung tissues and broncho-
alveolar spaces, accompanied by decreased pulmonary injury [36].
Given that hyperoxia-induced stress was shown to activate TLRs
[37], it is of interest to determine if uPAR also regulates hyperoxia
induced inflammatory cell activation. Previous studies demon-
strated that uPAR expression is upregulated in monocytes by
endotoxin [15,16,17,18,19]. In our study, we did not find a
noticeable increase in uPAR expression up to two hours after
PAM stimulation in neutrophils. However, it remains possible that
uPAR expression may be increased at later time points after PAM
treatment and such enhanced expression of uPAR may then
contribute to enhanced TLR2 induced neutrophil activation.
Excessive and uncontrolled inflammation after bacterial infec-
tion is a leading factor contributing to sepsis, and associated
multiple organ dysfunction and death [38,39]. TLR2 ligands
include major components on the surface of both gram-positive
and gram-negative bacteria, including peptidoglycans and lipo-
proteins [1,2,3,4]. Therefore, neutrophil associated uPAR could
be a potential target for treating acute inflammation, sepsis, and
organ injury related to severe bacterial and other microbial
infections in which TLR2 engagement plays a major role.
Materials and Methods
Materials
Custom cocktail antibodies and negative selection columns for
neutrophil isolation were purchased from StemCell Technologies.
Brewer thioglycollate was from Sigma-Aldrich. LPS from
Escherichia coli 0111:B4 and rabbit anti-actin antibodies were from
Sigma-Aldrich. PAM3CSK4 (PAM) was from Invivogene. Anti-
bodies specific for phosphorylated ERK, phosphorylated-p38,
total p38, and IkB-a were from Cell Signaling. Goat anti-uPAR
was from R&D. Rabbit anti-GAPDH antibodies were from Santa
Cruz. Control siRNA and uPAR siRNA were purchased from
Dharmacon.
Mice
uPAR knockout mice that have been backcrossed with C57/
BL6 mice for at least nine generations were obtained from Dr.
Margaret Gyetko (University of Michigan). Age-and sex-matched
control C57/BL6 mice were purchased from NCI-Fredrick. 8-10
week old animals were used for experiments. Animal protocols
were approved by the Institutional Animal Care and Use
Committee of the University of Alabama at Birmingham.
Isolation and culture of bone marrow neutrophils
Isolation of bone marrow neutrophils was performed as
previously described [40].
In vivo acute lung injury model (ALI)
The murine ALI model was used as previously described
[20,23]. Briefly, mice were anesthetized with isoflurane. The
tongue was then gently extended and a solution of PAM (200 mg
PAM/mouse in 50 ml LPS) or LPS (50 mg LPS/mouse in 50 ml
PBS) was deposited into the oropharyx. At 24 hours after the PAM
or LPS injection, mice were sacrificed and bronchoalveolar lavage
(BAL) samples obtained.
Harvest of bronchoalveolar lavage (BAL) fluid
BAL samples were obtained from PAM or LPS-treated mice by
securing a polyethylene catheter in the trachea and then lavaging
the lungs three times with 1 ml of iced PBS. Levels of TNF-a in
the BAL were determined by ELISA. Total cell counts were
measured in the BAL fluid with a hemocytometer and protein
concentrations were determined with a Bio-Rad protein assay kit.
Intraperitoneal injection of PAM in mice
Solutions of PAM (200 mg PAM/mouse in 200 ml PBS) were
injected intraperitoneally. At 6 hours after the injections, mice
were sacrificed and blood was collected from the retro-orbital
venous plexus.
Western blotting assay
Western blotting assays were performed as previously described
[41].
Cytokine ELISA and protein assays
Immunoreactive TNF-a was quantified using DuoSet ELISA
Development kits (R&D Systems) according to the manufacturer’s
instructions.
EMSA
Nuclear extracts were prepared and assayed by EMSA as
previously described [23]. For analysis of NF-kB, the kB DNA
sequence of the Ig gene was used. Synthetic double-stranded
sequences (with enhancer motifs underlined) were filled in and
labeled with [c-
32P] dATP (Perkin-Elmer) using T4 polynucleotide
kinase as follows: kB sequence, 59-GCCATGGGGGGATCCCC-
GAAGTCC-39 (promega).
siRNA transfection
WT macrophages were plated in 24 or 48 well plates. One day
after cell plating, the cells were transfected with 40 nM control
siRNA or uPAR siRNA using HiperFect transfection reagents
(Qiagen) according to the manufacturer’s instructions. Three days
after transfection, the cells were collected for Western blotting or
treated with PAM or LPS.
Statistical analysis
For each experiment, macrophages or neutrophils were isolated
and pooled from groups of mice (n=3–4). One representative
experiment is shown for most conditions. Each experiments were
performed 2–3 times independently, using cells from different
groups of mice on different days and showed similar results. One
way analysis of variance (ANOVA) for multiple groups followed by
the Tukey-Kramer test, or Student’s t test for comparisons
between two groups was used. p,0.05 was considered to be
statistically significant.
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